Summary & Overview
CPT 81437: Hereditary Colon Cancer Genomic Sequence Analysis Panel
CPT code 81437 represents a comprehensive genomic sequence analysis panel for hereditary colon cancer disorders, including conditions such as Lynch syndrome and PTEN hamartoma syndrome. This code is significant nationally as it enables laboratories to provide advanced genetic testing that can identify individuals at risk for inherited colorectal cancer syndromes, supporting early detection and targeted clinical management. The service is typically performed in laboratory settings and is a cornerstone in precision medicine for cancer prevention.
Major payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will gain insights into payer coverage policies, clinical benchmarks, and recent policy updates relevant to genetic testing for hereditary colon cancer. The publication also provides context on associated diagnoses, related CPT codes, and the role of genetic testing in modern oncology practice. This summary is designed to inform stakeholders about the evolving landscape of genetic testing reimbursement, clinical utility, and coding practices for hereditary colon cancer panels.
CPT Code Overview
CPT 81437 is used for genomic sequence analysis panels targeting hereditary colon cancer disorders, such as Lynch syndrome and PTEN hamartoma syndrome. This code requires sequencing of at least 10 genes, providing a comprehensive genetic assessment for individuals at risk of inherited colorectal cancer syndromes. The service type is genetic testing, and it is typically performed in a laboratory setting (POS 81). This testing plays a critical role in identifying genetic predispositions, guiding clinical management, and informing family risk assessments.
Clinical & Coding Specifications
Clinical Context
A patient with a family history of colon cancer or a personal history of colon neoplasms presents to their healthcare provider. The provider, often a specialist in medical genetics, determines that the patient may be at risk for hereditary colon cancer syndromes such as Lynch syndrome or PTEN hamartoma syndrome. The provider orders a comprehensive genomic sequence analysis panel, which includes sequencing of at least 10 genes associated with hereditary colon cancer disorders. The specimen is collected and sent to a laboratory (Place of Service 81) for analysis. Results are interpreted by a medical geneticist, and the findings guide further management, surveillance, or genetic counseling for the patient and potentially their family members.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the service, typically when the provider is responsible for interpreting the genetic test results but not performing the laboratory analysis. - Modifier
59: Used to indicate a distinct procedural service, such as when multiple genetic tests are performed that are not normally reported together.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code |
|---|